Ezetimibe added to atorvastatin compared with doubling the atorvastatin dose in patients at high risk for coronary heart disease with diabetes mellitus, metabolic syndrome or neither

• Published in: Diabetes, obesity & metabolism obesity & metabolism, 2010-03, Vol.12 (3), p.210-218
• Main Authors: Conard, S, Bays, H, Leiter, L.A, Bird, S, Lin, J, Hanson, M.E, Shah, A, Tershakovec, A.M
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents - administration & dosage; Arteriosclerosis; Atorvastatin; Atorvastatin Calcium; Azetidines - administration & dosage; Canada; Cardiovascular disease; Cholesterol; Coronary artery disease; Coronary Artery Disease - drug therapy; Coronary Artery Disease - prevention & control; Diabetes; Diabetes mellitus (non-insulin dependent); Diabetic Angiopathies - drug therapy; Diabetic Angiopathies - prevention & control; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination - methods; Ezetimibe; Heart diseases; Heptanoic Acids - administration & dosage; high coronary heart disease risk; High density lipoprotein; Humans; Hypercholesterolemia; Hypercholesterolemia - drug therapy; Lipids; Low density lipoprotein; Male; Metabolic syndrome; Metabolic Syndrome - complications; Metabolic Syndrome - drug therapy; Middle Aged; Patients; Pyrroles - administration & dosage; Risk Factors; Treatment Outcome; Triglycerides; type 2 diabetes mellitus; United States; Young Adult
• ISSN: 1462-8902; 1463-1326
• DOI: 10.1111/j.1463-1326.2009.01152.x

Aim: Type 2 diabetes mellitus (T2DM) and metabolic syndrome (MetS) are both associated with increased risk for atherosclerotic coronary heart disease (CHD). Thus, it is useful to know the relative efficacy of lipid-altering drugs in these patient populations. Methods: A double-blind, parallel group trial of adult patients with hypercholesterolaemia at high-CHD risk receiving atorvastatin 40 mg/day compared atorvastatin 40 mg plus ezetimibe 10 mg (ezetimibe) vs. doubling atorvastatin to 80 mg. This post hoc analysis reports lipid efficacy results in patients grouped by diagnosis of T2DM, MetS without T2DM or neither. Per cent change from baseline at week 6 was assessed for LDL-C, total cholesterol, HDL-C , non-HDL-C , Apo A-I, Apo B and triglycerides. Safety was monitored through clinical and laboratory adverse events (AEs). Results: Compared with doubling atorvastatin, atorvastatin plus ezetimibe resulted in greater reductions in LDL-C, triglycerides, Apo B, non-HDL-C, total cholesterol and lipid ratios in the T2DM, MetS and neither groups. Treatment effects were of similar magnitude across patient groups with both treatments, except triglycerides, which were slightly greater in the T2DM and MetS groups vs. neither group. Changes in HDL-C , Apo A-I and high sensitivity C-reactive protein (hs-CRP) were comparable for both treatments in all three groups. Safety and tolerability profiles were generally similar between treatments and across patient groups, as were the incidence of liver and muscle AEs. Conclusions: Compared with doubling atorvastatin to 80 mg, addition of ezetimibe to atorvastatin 40 mg produced greater improvements in multiple lipid parameters in high-CHD risk patients with T2DM, MetS or neither, consistent with the significantly greater changes observed in the full study cohort (clinical trial # NCT00276484).